1267-tetrahydro-8h-indeno[54-b]furan-8-one (Cas 196597-78-1)

We are instrumental in manufacturing exporting trading and supplying a supreme quality of 1267-Tetrahydro-8H-Indeno[54-B]Furan-8-One (CAS 196597-78-1) in Minhang Shanghai China which is a key intermediate for preparation of ramelteon a MT1 and MT2 melatonin receptor selective agonist.
Previously sleep agents bind to GABAA receptors which are associated with anxiolytic myorelaxant and amnesic effects such as with drugs like and . As the first in a new class of sleep agents Ramelteon selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN). It was developed by Takeda Pharmaceuticals North America with the trade name Rozerem and was approved by the U.S. Food and Drug Administration (FDA) on July 4th 2005 for long-term use. It can be used for insomnia delayed sleep onset in particular. There is no proof showing that Ramelteon produces dependence and any potential for abuse. What's more while there is withdrawal and rebound insomnia typically with GABA modulators it is not shown in ramelteon. Ramelteon can also be used for the treatment of Delayed sleep phase syndrome. Ramelteon was proven by practice to be associated with a lower risk of delirium (3% vs 32%; Pa =a .003). According to Chakraborti D; Tampi D. J.; Tampi R. R. (2014) ("Melatonin and Melatonin Agonist for Delirium in the Elderly Patients").